The European Commission announced, on Tuesday 6 June, that it had authorised Arexvy, the first vaccine designed to protect adults aged 60 and over against lower respiratory tract disease caused by the respiratory syncytial virus (RSV).
The Arexvy vaccine, which is now authorised throughout the EU, will help strengthen the immune response to the virus. The authorisation follows a rigorous assessment under the European Medicines Agency’s (EMA) accelerated assessment mechanism. Considering...